[Benign prostatic syndrome (BPS). Ablative treatments]

Urologe A. 2006 Jun;45(6):769-80; quiz 781-2.
[Article in German]

Reich O, Seitz M, Gratzke C, Schlenker B, Bachmann A, Stief C.

Urologische Klinik und Poliklinik, Klinikum Grosshadern, Ludwig-Maximilians-Universit?t, 81377 , M?nchen, oreich@med.uni-muenchen.de

Today, the surgical treatment of the benign prostatic syndrome (BPS) often follows a course of drug treatment. Besides conventional transurethral resection of the prostate (TURP), which has represented the standard therapeutic option for decades, and its in part significant modifications (”vaporizing resection”; bipolar resection), much of the interest has shifted to alternative instrumental procedures like transurethral microwave therapy (TUMT), transurethral needle ablation of the prostate (TUNA) or several laser techniques. By reviewing the current literature, preferably from randomized controlled trials, these different procedures are critically assessed. Moreover, the present role of open prostatectomy is discussed.

• Enlarging the scope of managing benign prostatic hyperplasia: addressing sexual function and quality of life.
• Transurethral electrovaporization of the prostate (TUVP) is effective, safe and durable.
• Erectile dysfunction following transurethral resection of the prostate.
• Incidence of erectile impotence secondary to transurethral resection of benign prostatic hyperplasia, assessed by preoperative and postoperative Snap Gauge tests.
• Transurethral incision versus transurethral resection of the prostate for the treatment of benign prostatic hypertrophy. A preliminary report.